The concept of combination therapy in acute ischemic stroke
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Acute ischemic stroke is usually caused by thromboembolic occlusion of an intracranial artery.1 The arterial occlusion and the consequent lowering of CBF result in a complex series of events that transform ischemic tissue into infarction.2,3 The survival time of tissue after ischemia depends mainly on the residual CBF through collaterals and on selective neuronal vulnerability to ischemia.3 The time window from ischemia to neuronal death therefore varies widely. It may be a few minutes, e.g., in brain tissue with a residual CBF below 10 ml/100 g/min (the so-called threshold for energy failure), or several hours, e.g., in tissue with CBF values between 10 and 20 ml/100 mg/min (the ischemic penumbra). In the context of penumbra tissue, the electrical neuronal function is abolished but the neurons themselves are viable4 until the amount of ATP produced falls below 50% of normal values and the breakdown of energy-producing metabolites causes lactoacidosis, ion pump failure, and eventually irreversible membrane damage5 (figure 1). As a consequence, tissue that at a certain point in time is alive or can be saved from ischemia may be irreversibly damaged soon after. In other words, there is a "point of no return" in the ischemic cascade, a factor that is crucial for both the so called therapeutic window6 and for acute stroke treatments.
Figure 1. Main steps of the ischemic cascade. EAA= excitatory amino acids, Cai = intracellular calcium, Nai= intracellular sodium, Ke = extracellular potassium, ICAM-1 = intercellular adhesion molecules.
Ischemia may be reversed by reperfusion.7 However, on return of blood flow, together with the resumption of the principal neuronal functions (e.g., oxygen delivery, provision of substrates for metabolism), interactions between blood and the already damaged tissue can be responsible for further tissue …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
Applications of diffusion–perfusion magnetic resonance imaging in acute ischemic strokeMarc Fisher, Gregory W. Albers et al.Neurology, June 01, 1999 -
Introduction
Advances in stroke managementDavid G. Sherman et al.Neurology, November 01, 1997 -
Periprocedural Management
Periprocedural management of acute ischemic stroke interventionNicholas Tarlov, Yih Lin Nien, Osama O. Zaidat et al.Neurology, September 24, 2012 -
VIEWS AND REVIEWS
Evolving stroke and the ischemic penumbraMarc Fisher, Julio H. Garcia et al.Neurology, October 01, 1996